1. Post-Approval (Phase 4) ResearchOnce Anavex receives regulatory approval (for example, for blarcamesine / ANAVEX®2-73 in Alzheimer’s, Rett, or Parkinson’s dementia), the regulators — FDA, EMA, etc. — often require or encourage post-marketing studies to:
The Partex AI platform and patient app ecosystem could collect and analyze real-world data from approved drug users — continuously, in real time — which is exactly what’s needed for those studies.
Example:Patients (or caregivers) using the app can record:
That data can be securely anonymized, aggregated, and fed into:
This reduces the need for traditional, expensive follow-up trials — because the RWD pipeline is continuous and AI-assisted.
Market Data 
Markets 
